mTOR in tuberous sclerosis and other neurological disorders.
Franz
David Neal
DN
D004827:Epilepsy / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D009422:Nervous System Diseases / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D011494:Protein Kinases / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D016896:Treatment Outcome; D014402:Tuberous Sclerosis / Q000235:genetics / Q000503:physiopathology*
D007166:Immunosuppressive Agents; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus